An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared With Sevelamer Carbonate Followed by a Randomised Comparison of PA21 Maintenance Dose Versus PA21-Low Dose in Dialysis Patients With Hyperphosphataemia

Trial Profile

An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared With Sevelamer Carbonate Followed by a Randomised Comparison of PA21 Maintenance Dose Versus PA21-Low Dose in Dialysis Patients With Hyperphosphataemia

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Sucroferric oxyhydroxide (Primary) ; Sevelamer
  • Indications Hyperphosphataemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Vifor Pharma
  • Most Recent Events

    • 01 Apr 2017 Results (n=213) comparing efficacy and safety of sucroferric oxyhydroxide with sevelamer hydrochloride published in the Nephrology.
    • 23 Feb 2017 Results (n=1055) of both parent and extension study assessing one year efficacy and safety published in the Nephrology Dialysis Transplantation.
    • 23 Jun 2016 Results of post-hoc analysis of patients who completed 52 weeks of continuous treatment (n = 549) from this trial and its extension trial (NCT01464190) published in the Nephrology Dialysis Transplantation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top